Back to Journals » OncoTargets and Therapy » Volume 9

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

Authors Ricciardi GRR, Franchina T, Russo A, Schifano S, Ferraro G, Adamo V

Received 7 March 2016

Accepted for publication 7 May 2016

Published 21 July 2016 Volume 2016:9 Pages 4351—4355


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Professor Min Li

Giuseppina Rosaria Rita Ricciardi, Tindara Franchina, Alessandro Russo, Silvia Schifano, Giuseppa Ferraro, Vincenzo Adamo

Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy

Abstract: Neoadjuvant therapy is a well-established approach for the treatment of locally advanced or inflammatory breast cancer (BC) and has been increasingly used in recent years not only as a management strategy but also as a research tool. Recently, nanoparticle albumin-bound paclitaxel (nab-paclitaxel)/trastuzumab combinations have been associated with promising activity in different clinical settings. In the present case, we report a complete pathological response after neoadjuvant treatment with the trastuzumab/nab-paclitaxel combination in a locally advanced human epidermal growth factor receptor 2 (HER2)-positive BC patient, with a good toxicity profile. This combination may represent a valid therapeutic option in the neoadjuvant therapy for HER2-positive locally advanced BC.

Keywords: breast cancer, HER2-positive, nab-paclitaxel, trastuzumab, neoadjuvant therapy, pathologic complete response

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]